Suppressing NEAT1 impedes the migration and invasion capabilities of glioma cells by modulating the expression of SOX2, targeted by miR-132, underscoring NEAT1’s significance in glioma progression and its potential as a therapeutic target (Zhou et al., 2018). The gene discussed is SOX2; the disease is central nervous system cancer.